ZANTE GREG
Chief Financial Officer
ZANTE GREG has filed 3 SEC Form 4 filings (10 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Jul 30, 2026.
On the most recent filing, ZANTE GREG is listed as Chief Financial Officer at Viking Therapeutics, Inc. Inside the rolling window, ZANTE GREG reported no open-market purchases and 3 open-market sales totaling $2.8M in VKTX. The largest disclosed transaction in the window is a sale of 57,661 VKTX shares on Jan 5, 2026, worth $1.9M.
Companies traded
Other insiders at VKTX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.8M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has ZANTE GREG made?
ZANTE GREG has filed 3 SEC Form 4 filings (10 transaction rows) across 1 company since 2025.
Which companies does ZANTE GREG trade?
ZANTE GREG has filed SEC Form 4 disclosures for 1 company, including VKTX.
When was ZANTE GREG's most recent SEC Form 4 filing?
ZANTE GREG's most recent SEC Form 4 filing on Tracefour is dated Jul 30, 2026.
What is ZANTE GREG's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, ZANTE GREG is listed as Chief Financial Officer.
What is ZANTE GREG's total buy and sell value in the current window?
Inside the rolling retention window, ZANTE GREG bought $0 and sold $2.8M based on SEC Form 4 filings.
What was ZANTE GREG's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 57,661 VKTX shares on 2026-01-05, worth $1.9M, per SEC Form 4 filings.